Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 161 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR HGTV Star Hilary Farr Shares Breast Cancer Battle December 16, 2021 Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 Our COVID-19 Response: How GreaterGood Is Making An Impact During The... April 23, 2020 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Load more HOT NEWS Cannabis, cannabinoids and cancer – the evidence so far Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations Quizartinib Approval Adds New Treatment Option for AML, Including in Older...
